Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

Foreword – touchREVIEWS in RMD, Volume 4, Issue 1, 2025

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Psoriasis

Siew Eng Choon, Dermatology Meeting News 2021: Unmet Needs in Generalised Pustular Psoriasis

Published Online: Jun 15th 2021

It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the current unmet needs in the treatment of generalised pustular psoriasis (GPP).

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.

Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, Pfizer, GlaxoSmithKline, UCB, MSD and Wyeth.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.

Filmed in coverage of the AAD VMX 2021.

Alan Menter, Dermatology Meeting News 2023: Ixekizumab treatment for patients with moderate-to-severe plaque psoriasis

Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a post-hoc analysis conducted on trials studying the use of ixekizumab in adult and paediatric patients […]

Related Videos in Psoriasis

Developed by Touch

Alan Menter, Dermatology Meeting News 2023: Clinical presentations and unmet needs of palmoplantar psoriasis

Palmoplantar psoriasis has a significant impact on patients’ quality of life and can be challenging to treat. touchIMMUNOLOGY were delighted to speak with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA), about the prevalence and clinical presentations of ...

Developed by Touch

Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis

Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY ...

Developed by Touch

William Damsky, Dermatology Meeting News 2023: A personalised approach to treating inflammatory skin diseases

Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, ...

Developed by Touch

William Damsky, Dermatology Meeting News 2023: Current treatment paradigm and major challenges in treating inflammatory skin diseases

There are numerous therapeutics available to patients with inflammatory skin diseases, including TNF-alpha inhibitors, IL inhibitors, TYK2 and JAK inhibitors, optimising the use of these therapies could be achieved with a personalised approach to treatment. We were delighted to speak ...

Developed by Touch

Loretta Fiorillo: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis

Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how well the primary and secondary outcome measures were achieved. The abstract ‘Efficacy and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From a Phase 3, Randomized, Double Blind, Placebo-Controlled Study.’ ( Presentation ID D1T01.3E) was presented at EADV 2022, 7-10 September, 2022. Questions What were the aims, design and eligibility criteria of the study you are presenting? (0:26) What were the primary and secondary outcome measures and how well were they achieved at 16 weeks? (2:13) What are the clinical implications of these findings? (3:25) Disclosures: Loretta Fiorillo discloses receiving grant/ research support from Amgen, Pfizer, Galderma, Leo, and Timber; and serving on advisory boards for Amgen, Pfizer, Galderma, Leo, and Timber. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.

Developed by Touch

Loretta Fiorillo: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients

Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract 'Efficacy and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From a Phase 3, Randomized, Double Blind, Placebo-Controlled Study.' ( Presentation ID D1T01.3E) was presented at EADV 2022, 7-10 September, 2022. Questions: What are the unmet needs in the treatment of plaque psoriasis in paediatric patients? (0:26) What is apremilast, and what clinical evidence supports its use in the treatment of plaque psoriasis? (2:16) Disclosures: Loretta Fiorillo discloses receiving grant/ research support from Amgen, Pfizer, Galderma, Leo, and Timber; and serving on advisory boards for Amgen, Pfizer, Galderma, Leo, and Timber. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.

Developed by Touch

Linda Stein Gold: Quality of Life and Clinical Efficacy Findings from PSOARING 1 and PSOARING 2

PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) were two phase 3 trials investigating tapinarof cream, a novel, steroid-free, AhR modulating agent for the treatment of plaque psoriasis. It was a pleasure to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) around the aims, design, endpoints and quality of life and clinical efficacy findings from the two pivotal phase 3 trials. The abstract 'Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials.' (Abstract number: 1175) was presented at EADV 2022, 7-10 September, 2022. Questions What were the aims and design of the PSOARING 1 and PSOARING 2 studies? (0:18) How well were the endpoints of the studies achieved? (1:16) What were the findings that you presented at EADV? (2:17) Disclosures: Linda Stein Gold discloses consulting for Dermavant, Arcutis, Leo and Ortho Derm; receiving grant/ research support from Dermavant, Arcutis, Leo and Ortho Derm; serving on advisory boards for Dermavant, Arcutis, Leo and Ortho Derm; receiving honoraria from Dermavant, Arcutis, Leo and Ortho Derm and participating in speaker’s bureaus for Dermavant, Arcutis, Leo and Ortho Derm. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.

Developed by Touch

Linda Stein Gold: Tapinarof Cream 1% for the Treatment of Plaque Psoriasis

Tapinarof cream 1% once daily, a topical aryl hydrocarbon receptor (AhR)-modulating agent was recently approved by the FDA for the treatment of plaque psoriasis. touchIMMUNOLOGY were delighted to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to learn more about the unmet needs in the treatment of plaque psoriasis, the rationale for the use of tapinarof cream 1% in this indication and how the recent FDA approval will impact the treatment paradigm. The abstract 'Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials.' (Abstract number: 1175) was presented at EADV 2022, 7-10 September, 2022. Questions What are the unmet needs in the treatment of plaque psoriasis? (0:17) What is the mechanism of action of Tapinarof cream 1% and the rationale for its use in plaque psoriasis? (0:51) Following FDA approval, where does Tapinarof cream 1% fit in the treatment paradigm for plaque psoriasis? (1:28) Disclosures: Linda Stein Gold discloses consulting for Dermavant, Arcutis, Leo and Ortho Derm; receiving grant/ research support from Dermavant, Arcutis, Leo and Ortho Derm; serving on advisory boards for Dermavant, Arcutis, Leo and Ortho Derm; receiving honoraria from Dermavant, Arcutis, Leo and Ortho Derm and participating in speaker's bureaus for Dermavant, Arcutis, Leo and Ortho Derm. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.

Developed by Touch

Joel M Gelfand, Dermatology Meeting News 2022: Apremilast Impact on Vascular Inflammation and Cardiometabolic Function in Psoriasis

We caught up with Dr. Joel M. Gelfand (Penn Medicine; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to discuss the findings from the phase IV study, investigating the impact of apremilast on vascular inflammation and cardiometabolic function ...

Developed by Touch

Andrew Blauvelt, Dermatology Meeting News 2022: Malignancy Rates from a 5 Year Follow Up Study of the VOYAGE 1 and 2 Trials

touchIMMUNOLOGY were delighted to talk to Dr. Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) around the 5 year follow up study of the VOYAGE 1 and 2 trials, investigating guselkumab in patients with moderate to severe psoriasis. The abstract ‘Malignancy Rates ...

Andy Blauvelt: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis

touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis. His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp Psoriasis: Analysis of the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials’ was given at the EADV 30th Congress, 29 Sep - 2 Oct. Questions Could you tell us a little about deucravacitinib and POETYK PSO-1 and POETYK PSO-2 studies? (0:18) What were the efficacy findings from the primary data analysis? (2:14) What questions remain unanswered and where do you see deucravacitinib fitting in the treatment of scalp psoriasis? (4:22) Disclosures: Dr Andy Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome. Support: Interview and filming supported by Touch Medical Media. Interview conducted by Matthew Goodwin. Filmed in coverage of the EADV’s 30th Congress, 29 Sep - 2 Oct 2021. This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.

Leon Kircik, Dermatology Meeting News 2021: Roflumilast Foam in Scalp and Body Psoriasis

Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Foreword – touchREVIEWS in RMD, Volume 4, Issue 1, 2025

Conference Coverage

Learning Activities

Journals

Foreword – touchREVIEWS in RMD, Volume 4, Issue 1, 2025

Siew Eng Choon, Dermatology Meeting News 2021: Unmet Needs in Generalised Pustular Psoriasis

Alan Menter, Dermatology Meeting News 2023: Ixekizumab treatment for patients with moderate-to-severe plaque psoriasis

Alan Menter, Dermatology Meeting News 2023: Clinical presentations and unmet needs of palmoplantar psoriasis

Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis

William Damsky, Dermatology Meeting News 2023: A personalised approach to treating inflammatory skin diseases

William Damsky, Dermatology Meeting News 2023: Current treatment paradigm and major challenges in treating inflammatory skin diseases

Loretta Fiorillo: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis

Loretta Fiorillo: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients

Linda Stein Gold: Quality of Life and Clinical Efficacy Findings from PSOARING 1 and PSOARING 2

Linda Stein Gold: Tapinarof Cream 1% for the Treatment of Plaque Psoriasis

Joel M Gelfand, Dermatology Meeting News 2022: Apremilast Impact on Vascular Inflammation and Cardiometabolic Function in Psoriasis

Andrew Blauvelt, Dermatology Meeting News 2022: Malignancy Rates from a 5 Year Follow Up Study of the VOYAGE 1 and 2 Trials

Andy Blauvelt: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis

Leon Kircik, Dermatology Meeting News 2021: Roflumilast Foam in Scalp and Body Psoriasis

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Trending Topic

Connect With Us:

Siew Eng Choon, Dermatology Meeting News 2021: Unmet Needs in Generalised Pustular Psoriasis

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Functionality is for
Members Only